Results 1 to 10 of about 19,009 (196)
Background Hypomethylating agents (HMAs) have shown efficacy in the treatment of hematological malignancies and are indicated for the treatment of chronic myelomonocytic leukemia (CMML).
Ankur Sheel +5 more
doaj +2 more sources
Absence of early platelet increment in healthy mice during decitabine treatment
Treatment of myelodysplastic syndromes includes the administration of the hypomethylating agent decitabine. An early platelet response in decitabine-treated myelodysplastic syndrome patients is a predictor of overall survival. The effect of decitabine on
Juliane Baumann +4 more
doaj +2 more sources
Background Despite its inconsistent response rate, decitabine, a demethylating agent, is often used as a non-intensive alternative therapeutic agent for acute myeloid leukemia (AML). It has been reported that relapsed/refractory AML patients with t(8;21)
Shujiao He +6 more
doaj +1 more source
Decitabine suspends human CD34+ cell differentiation and proliferation during lentiviral transduction. [PDF]
Efficient ex vivo transduction of hematopoietic stem cells (HSCs) is encumbered by differentiation which reduces engraftment. We hypothesized that inhibiting DNA methyltransferase with decitabine would block differentiation of transduced CD34+ cells ...
Naoya Uchida +4 more
doaj +1 more source
BackgroundCD4+ T cells play multiple roles in controlling tumor growth and increasing IFN-γ+ T-helper 1 cell population could promote cell-mediated anti-tumor immune response.
Xiang Li +9 more
doaj +1 more source
Myelodysplastic syndrome (MDS) is a clonal hematopoietic stem cell disease characterized by inefficient hematopoiesis and the potential development of acute leukemia.
Seungyoun Kim +6 more
doaj +1 more source
Background Targeting the epigenome of cancerous diseases represents an innovative approach, and the DNA methylation inhibitor decitabine is recommended for the treatment of hematological malignancies.
Zijiao Tang, Lu Liu, Jürgen Borlak
doaj +1 more source
Decitabine combined with RDHAP regimen in relapsed/refractory diffuse large B cell lymphoma
Background There is an urgent need for effective treatment of patients with relapsed/refractory diffuse large B‐cell lymphoma (R/R‐DLBCL). This trial investigated the efficacy of decitabine in combination with rituximab, cisplatin, cytarabine ...
Xiaoshuang Kong +15 more
doaj +1 more source
Background Programmed death-1 (PD-1) blockade monotherapy induced durable remission in a subset of patients with relapsed/refractory classical Hodgkin lymphoma (cHL). We asked whether the anti-PD-1 agent, camrelizumab, combined with the DNA demethylating
Weidong Han +7 more
doaj +1 more source
Abnormal Ferroptosis in Myelodysplastic Syndrome
BackgroundFerroptosis is a form of iron-dependent non-apoptotic cell death, with characteristics of loss of the activity of the lipid repair enzyme, glutathione (GSH) peroxidase 4 (GPX4), and accumulation of lethal reactive lipid oxygen species.
Qi Lv +10 more
doaj +1 more source

